Longitudinal changes in %FEV1 measurements collected while on ruxolitinib therapy. Graphical representation of longitudinal demonstrates the %FEV1 measurements for participants who were responders (PR or CR by NIH criteria, n = 17) in red and nonresponders (n = 32) in gray. Fitted lines for responders and nonresponders generated using locally weighted smoothing (LOESS technique) to visually present the relationship between %FEV1 and response over time. LOESS, locally estimated scatterplot smoothing.